cemka > Publications > Neurologie

Classer les publications sur l'année

  • Pharmaco-EpidĂ©miologie

    Epidemiology of restless legs syndrome in French adults A nationwide survey: The INSTANT Study

    TISON F, CROCHARD A, LEGER D, BOUEE S, LAINEY E, EL HASNAOUI A

    Neurology ; 65:239-246

  • Pharmaco-EpidĂ©miologie

    Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs : a prospective European study

    PECHEVIS C, CLARKE E, VIEREGGE P, KHOSHNOOD B, DESCHASEAUX-VOINET C, BERDEAUX G, ZIEGLER M

    Eur J Neurol ; 12:956-963

  • Pharmaco-EpidĂ©miologie

    Screening for Alzheimer’s disease with the short cognitive evaluation battery

    ROBERT PH, SCHUCK S, DUBOIS B, OLIE JP, LEPINE JP, GALLARDA T, GONI S, TROY S

    Dement Geriatr Cogn Disord ; 15:92-98

  • Économie de la santĂ©

    Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications

    FAGNANI F, LAFUMA A, PECHEVIS M, RIGAUD AS, TRAYKOV L, SEUX ML, FORETTE F

    Dement Geriatr Cogn Disord ; 17(1-2):5-13

  • Économie de la santĂ©

    Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease

    RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FORETTE F

    J Geriatr Psychiatry Neurol ; 16(3):140-145

  • Économie de la santĂ©

    Patients with Alzheimer’s disease living at home in France : costs and consequences of the disease

    RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FLORETTE F

    J Geriatr Psychiatry Neurol ; 16(3):140-145

  • Économie de la santĂ©

    The Value of Economic Modeling Studies in the Evaluation of Treatment Strategies for Multiple Sclerosis

    DETOURNAY B

    Value Health ; 5(1):1-2

  • Pharmaco-EpidĂ©miologie

    Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study

    JALLON P, LOISEAU P, LOISEAU J, CAROLE, on behalf of Groupe

    Epilepsia ; 2001;42 (4): 464-475

  • Pharmaco-EpidĂ©miologie

    L’observatoire du traitement mĂ©dical de la maladie d’Alzheimer en neurologie libĂ©rale et les contrĂŽles de qualitĂ© dans les Ă©tudes pharmaco-Ă©pidĂ©miologiques

    SIMON T, HINAULT P, GONI S, HOTTON JM, PAUL-DAUPHIN A, GUARD O, DARAN H, JAILLON P

    La Lettre du Pharmacologue ; 15(4):74-78

  • Économie de la santĂ©

    Les patients atteints d’Alzheimer Ă  domicile : coĂ»t et retentissement de la maladie

    RIGAUD AS, BAYLE C, FORETTE F, BUTEAU L, FAGNANI F

    GĂ©rontologie ; 2001(115): 17-23

  • Pharmaco-EpidĂ©miologie

    Direct and indirect costs of Parkinson’s Disease (PD) and L-Dopa-Induced Dyskinesia: a Prospective European Study (Abstract)

    PECHEVIS M, CLARKE CE, VIEREGGE P, ZIEGLER M, BERDEAUX G, BARLAND JC, J, GARDNER

    Parkinsonian & Related Disorders ; 7(P-WE-383):S106

  • Économie de la santĂ©

    Evaluation économique du dispositif transdermique de Fentanyl dans la prise en charge de la douleur cancéreuse

    PECHEVIS M, EMERY C, FAGNANI F

    La Lettre du Pharmacologue ; 14 (1) ; 10-14

  • Pharmaco-EpidĂ©miologie

    DĂ©lais Ă©volutifs des syndromes Ă©pileptiques avant leur diagnostic : rĂ©sultats descriptifs de l’enquĂȘte CAROLE

    Groupe CAROLE

    Revue de Neurologie ; 2000;156; (5) : 481-490

  • Pharmaco-EpidĂ©miologie

    ESPERA study : Applicability of the new ILAE criteria for antiepileptic drug resistance of focal epilepsies in current clinical practice

    DE TOFFOL B, DE ZELICOURT M, VESPIGNANI H, FAGNANI F, LAURENDEAU C, LEVY-BACHELOT L, MURAT C, GASALLA T, ARZIMANOGLOU A, VILLANUEVA V

    Epilepsy Behav ; 2012;25(2):166-169

  • Économie de la santĂ©

    Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study

    VILLANUEVA V, GIRÓN JM, MARTÍN J, HERNÁNDEZ-PASTOR LJ, LAHUERTA J, DOZ M, CUESTA M, LÉVY-BACHELOT L; INVESTIGADORES DEL ESTUDIO ESPERA

    Neurologia ; 2013;28(4):195-204